ClinicalTrials.gg
RecruitingNCT07010315Updated Aug 6, 2026

Development and Testing of a Patient-facing Educational Tool About Liver Cancer Prevention

An observational study in Liver Cancer, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by M.D. Anderson Cancer Center · Observational

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.
Study type
Observational
Model
Ecologic or community
Time perspective
Cross-sectional
Enrollment
40
Ages
18 Years and older
Sex
All
01

Study summary

To develop and test liver cancer prevention educational material.

Read the detailed description

Primary Objectives:

  • To ensure the text for the site is understood by participants, participant comprehension will be measured qualitatively through cognitive testing. Adjustments will be made to the content, messages, and layout iteratively until interviewer notes show no large discrepancies between participant understanding and the meaning of the text.
  • To ensure the site is easy to use, usability will be measured qualitatively through usability testing. Adjustments will be made to the functionality of the patient-facing portions of the web-based tool iteratively until interviewer notes indicate that participants are able to input their risk factors and download the personal summary on their own.

Secondary Objectives:

  • To describe whether the site is acceptable to users, acceptability will be measured (as part of usability testing) with the Ottawa Acceptability Measures.
  • To describe participants' knowledge of liver cancer risk factors, knowledge will be measured (as part of usability testing) with Knowledge Questions developed for this study.
02

Conditions studied

  • Liver Cancer

Keywords

  • Liver cancer
  • Liver disease
  • Fibrosis
  • Cirrhosis
03

In context

Liver Neoplasms

1,345 studies on the registry are indexed under Liver Neoplasms; 335 are open to participants now.

This study's planned enrollment of 40 is below the median of 200 across 342 observational studies indexed under Liver Neoplasms.

Browse Liver Neoplasms studies →

Lead sponsor

M.D. Anderson Cancer Center is the lead sponsor of 3,047 studies on the registry; 578 are open to participants now.

Of its 612 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants at HOPE Clinic

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years old
  • Participants at the HOPE Clinic
  • Able to speak and read either English or Spanish
  • For usability testing: Able to use and navigate websites on own smart phone or study computer

Exclusion criteria

Exclusion Criteria:

  • Has been diagnosed with liver cancer
  • Cannot provide consent or otherwise participate in research activities (e.g. vision or hearing impairment)
05

Study design

Observational model
Ecologic or community
Time perspective
Cross-sectional
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cognitive Interviews (English and Spanish)

    Participants that agree to this part of the study will be asked to view patient education materials about liver cancer, complete a demographic survey, and do an interview one-on-one either online via Zoom, over the phone, or in person at HOPE Clinic.

    Behavioral: Cognitive Testing

  • Usability Testing (English and Spanish)

    Participants will be asked to complete a pre-survey, navigate a liver cancer education website, provide their feedback and impressions, and complete a post- survey.

    Behavioral: Usability Testing

Interventions

  • BehavioralCognitive Testing

    Given by Survey and one-on one interviews

  • BehavioralUsability Testing

    Given by surveys and one-on-one interview.

06

What researchers measure

Primary outcomes

  1. Cognitive Testing

    Participant comprehension will be measured qualitatively through cognitive testing. In cognitive testing interviews, participants are asked to "think aloud" as they review and react to new information. Participants will be presented with the storyboard (mock-up) versions of the content and asked to describe in their own words what the information means to them. Cognitive interviews may include questions about content such as length, clarity of the language, and helpfulness of the educational material. A trained research team member will ask probing questions throughout interviews as needed. Based on patient feedback, modifications will be made iteratively to the content to ensure the content is understood and interpreted as intended. There is no post-survey for cognitive testing.

    Time frame: Up to 1.5 hours

  2. Usability Testing

    Usability will be measured qualitatively using a Usability Interview Guide. Usability will also be measured using the System Usability Scale. Acceptability will be measured with the Ottawa Acceptability Measures. Knowledge will be measured pre- and post- session using knowledge questions developed by the investigators and refined during cognitive testing.

    Time frame: Up to 1.5 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07010315
Collaborators
Cancer Prevention Research Institute of Texas
Responsible party
Sponsor
First posted
Jun 8, 2025
Start date
May 1, 2025
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Aug 6, 2026

Study contacts

Jessica Hwang, MD, MPH
Contact
jphwang@mdanderson.org
(346) 720-7352
Jessica Hwang, MD, MPH
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion